First Tracks Biotherapeutics Reports Third-Quarter Net Loss of $31.4M
The company’s diluted loss per share narrowed to $0.88 from $1.50 a year earlier. It also reported progress across its ANB033 and rosnilimab programs.
Story updates
09:40:30 PM UTC
SquawkNews
First Tracks Biotherapeutics Q3 2026 net loss narrows 25% to $31.36 million First Tracks Biother
First Tracks Biotherapeutics reported a net loss of $31.4M for the third quarter of 2026, compared with a $41.9M loss a year earlier, while diluted loss per share narrowed to $0.88 from $1.5. The company also reported progress across its ANB033 and rosnilimab programs.Financial HighlightsBusiness H…